MedTrace Logo

AMAZE™ Asthma Implementation QI Study

NCT04901260 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 117

Last updated 2022-08-01

No results posted yet for this study

Summary

The primary study objective is to generate evidence as to the feasibility, usability, perceived value, and potential benefits of implementing the AMAZE™ platform into clinical practice.

Conditions

Interventions

DEVICE

AMAZE™ Disease Management Platform

The disease management platform includes a patient mobile application where patients can enter daily symptoms, communicate with their healthcare providers, and access educational materials. Additionally, the healthcare providers will have access to a dashboard that is integrated with the EMR and patient app.

Sponsors & Collaborators

  • Greater Austin Allergy

    collaborator UNKNOWN

  • Evidera, Inc.

    collaborator UNKNOWN

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Eric Schultz, DO, MPH · GAA

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-25
Primary Completion
2021-06-30
Completion
2021-06-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04901260 on ClinicalTrials.gov